Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
44 results about "XIAP" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
X-linked inhibitor of apoptosis protein (XIAP), also known as inhibitor of apoptosis protein 3 (IAP3) and baculoviral IAP repeat-containing protein 4 (BIRC4), is a protein that stops apoptotic cell death. In humans, this protein (XIAP) is produced by a gene named XIAP gene located on the X chromosome.
Caspase-9 : BIR domain of XIAP complexes and methods of use
InactiveUS20040180828A1Avoid possibilityIncreased apoptosisPowder deliveryElectrotherapyApoptosisCaspase-9
The present invention provides polypeptides and specific binding agents that modify the activity of an initiator caspase involved in apoptosis, caspase-9. The polypeptides include the third baculoviral IAP repeat (BIR3) of an IAP and form a heterodimer complex with caspase-9. Nucleic acid molecules including expression vectors encoding the polypeptides and variants thereof as well as variants of caspase-9 are provided. Such polypeptide and nucleic acid molecules may be used for modifying apoptosis.
Owner:THE TRUSTEES FOR PRINCETON UNIV
Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
InactiveUS20070026076A1Increase the number ofEasy to demonstratePowder deliveryVirusesDendritic cellVaccine Potency
T cell immune responses are enhanced by presentation of antigen to CD8+ T cells using a chimeric nucleic acid immunogen or vaccine that links DNA encoding an antigen with DNA encoding a polypeptide that targets or translocates the antigenic polypeptide to which it is fused (immunogenicity-potentiating polypeptides or “IPP”). By inhibiting apoptosis in the vicinity of a T cell responses to such a nucleic acid immunogen, even more potent immune responses are attained. The present strategy prolongs the survival of DNA-transduced cells, including dendritic cells (DCs), thereby enhancing the priming of antigen-specific T cells and increase potency. Co-delivery of DNA encoding an inhibitor of apoptosis, including (a) BCL-xL, (b) BCL-2, (c) XIAP, (d) dominant negative caspase-9, or (e) dominant negative caspase-8, or (f) serine protease inhibitor 6 (SPI-6) which inhibits granzyme B, with DNA encoding an antigen, prolongs the survival of transduced DCs and results in significant enhancement of antigenspecific T cell immune responses that provide potent antitumor effects. Thus, co-administration of a DNA vaccine encoding antigen linked to an IPP along with one or more DNA constructs encoding an anti-apoptotic protein provides a novel way to enhance vaccine potency.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Guggulsterone: an inhibitor of nuclear factor - kappaB and IkappaBalpha kinase activation and uses thereof
InactiveUS20060019907A1Good effectHigh activityBiocideOrganic active ingredientsLymphatic SpreadCyclin D1
The present invention provides an inhibitor of NF-κB, guggulsterone and its analogs. Guggulsterone suppresses NF-κB activation induced by TNF, phorbol ester, okadaic acid, cigarette smoke, H2O2 and IL-1β, as well as constitutive NF-κB activation expressed in most tumor cells. One mechanism by which guggulsterone inhibits activation of NF-κB is through suppression of IκBα phosphorylation and IκBα degradation. NF-κB-dependent gene transcription is modulated by guggulsterone and its analogs. In particular, induction by TNF, TNFR1, TRADD, TRAF2, NIK and IKK, is modulated by guggulsterone and its analogs. In addition, guggulsterone decreased the expression of genes involved in anti-apoptosis (IAP1, XIAP, Bfl-1 / A1, bcl-2, cFLIP, survivin), proliferation (cyclin D1, c-myc) and metastasis (MMP-9, COX2 and VEGF).
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Organic Compounds
Owner:NOVARTIS AG
Organic compounds
Owner:NOVARTIS AG
Smac Mimetic Therapy
InactiveUS20140303090A1Dipeptide ingredientsMicrobiological testing/measurementSmac mimeticsCancer research
A Smac mimetic therapy wherein the Smac mimetic is selected and developed based at least in part on its poor inhibition of XIAP-dependent processes.
Owner:WALTER & ELIZA HALL INST OF MEDICAL RES +1
PI3K-Akt Pathway Inhibitors
InactiveUS20070238745A1Increase Bim abundanceBiocideAnimal repellantsProstate cancer cellMitochondrial pathway
A treatment for cancer using a combination therapy including an inhibitor of the PI3K / Akt pathway in combination with roscovitine. It is shown that the combination of roscovitine and API-2 (Triciribine) or roscovitine and LY294002 induce the apoptosis of androgen-dependent (LNCaP) and androgen-independent (PC3) prostate cancer cells. Two important results have been observed. First, cells that respond to roscovitine alone (LNCaP) initiate apoptosis sooner when co-treated. Second, cells that do not respond to roscovitine alone (PC3) apoptose when co-treated, although with delayed kinetics. In the absence of roscovitine, AKT inhibitors had no effect on LNCaP or PC3 survival, and in both cell lines, the combined treatment activated the mitochondrial pathway of apoptosis. Importantly, normal epithelial cells (RPWE) remained viable in the presence of roscovitine and AKT inhibitors. Events elicited by roscovitine (down-regulation of XIAP) and AKT inhibitors (accumulation of Bim) in LNCaP and PC3 cells are identified. Additional data show that PC3 cells apoptose when treated with AKT inhibitors and depleted of either XIAP or Cdk9. Taken together, these important results lead to improved treatments for cancers, such as prostate cancer, through the combination therapies taught herein.
Owner:UNIV OF SOUTH FLORIDA
XIAP therapy
InactiveUS20060269520A1Sufficient amountBiocideOrganic active ingredientsMedicineDegenerative Disorder
Owner:CHILDRENS HOSPITAL OF EASTERN ONTARIO
Double-target-spot fusion protein capable of enhancing TRAIL antitumor activity
InactiveCN103524627AImprove solubilityImprove recycling efficiencyPolypeptide with localisation/targeting motifPeptide/protein ingredientsTRAIL ProteinCell membrane
The invention belongs to the technical field of genetic engineering drugs, and discloses a double-target-spot fusion protein capable of enhancing the TRAIL antitumor activity. The cDNA sequence of the overall-length fusion gene sequence 1 is shown in SEQ ID NO1; the coding amino acid sequence of the overall-length fusion gene sequence 1 is shown in SEQ ID NO2; the coding cDNA sequence of the overall-length fusion gene sequence 2 is shown in SEQ ID NO4; and the coding amino acid sequence of the overall-length fusion gene sequence 2 is shown in SEQ ID NO5. In comparison with the prokaryotic expression carrier of separate TRAIL protein soluble fragment coding cDNA sequence, the fusion protein of the prokaryotic expression carrier has higher soluble expression, and the recycling and purifying efficiency of the fusion protein is higher; and the in-vitro biological activity analysis indicates that the fusion protein can activate death receptors on the cell membrane and inhibit expression of an XIAP gene in the cell plasma, enhance the activity of inducing tumor cell apoptosis through the double-target-spot function in apoptotic pathway and ensure stronger antitumor effect.
Owner:CHENGDU HUACHUANG BIOTECH CO LTD
Iap binding peptides and assays for identifying compounds that bind iap
InactiveUS20050176649A1Relieving IAP-mediated suppressionHigh throughput screeningDipeptide ingredientsMaterial analysis by observing effect on chemical indicatorInhibitor of apoptosisBinding peptide
Assays are disclosed for identifying peptides and peptidomimetics for promoting apotosis in cells, through a pathway involving the Inhibitor of Apoptosis Proteins (IAPs), exemplified by XIAP, and the mitochondrial protein Smac / DIABOLO (hereinafter Smac) and homologs thereof. Also disclosed are IAP-binding peptides and peptidomimetics identified through the use of the assay.
Owner:THE TRUSTEES FOR PRINCETON UNIV
Small molecule antagonists of XIAP family proteins
Owner:RGT UNIV OF MICHIGAN
Compounds that inhibit hsp90 protein-protein interactions with iap proteins
InactiveCN101065138APeptide/protein ingredientsApoptosis related proteinsIAP ProteinHSP90 Heat-Shock Proteins
Owner:UNIV OF MASSACHUSETTS
Method and antisense compound for potentiating anti-cancer agents
InactiveUS20050113328A1Increase lethalityEnhance lethality/doseOrganic active ingredientsBiocideCancer cellAnticarcinogen
A method and compound for enhancing the lethality of an anti-cancer therapy, such as radiation, chemotherapy, or TRAIL protein, are disclosed. The compound is composed of morpholino subunits joined by phosphorodiamidate linkages, and has a targeting sequence that is complementary to an AUG start, IRES, or splice-donor region of the transcript for human X-linked inhibitor of apoptosis protein (XIAP). The method includes exposing cancer cells to the compound.
Owner:AVI BIOPHARMA
Small peptide TAT-AVPY for treating ischemic brain damage, and application thereof
InactiveCN105777868ANo immunogenicityReduce the binding forcePeptide/protein ingredientsPeptidesSide effectApoptosis
The invention discloses a small peptide TAT-AVPY for treating ischemic brain damage, and an application thereof. The complete sequence of the small peptide TAT-AVPY is H-YGRKKRRQRRR-AVPY-OH, represented by SEQ ID NO:1. With the small peptide TAT-AVPY provided by the invention, the binding of XIAP and proaspase-9 (Casp 9) can be reduced; nitrosylation of XIAP and proaspase-9 (Casp 9) can be alleviated; and proaspase-9 activation can be alleviated. Therefore, cell apoptosis induced by cerebral ischemia can be alleviated. Also, TAT can directly bring fused small peptide into cells, such that a problem of the approach for the drug to enter cells is solved, and medication is convenient. The small peptide TAT-AVPY has no immunogenicity, and does not cause an immune response of a body. Therefore, side effects are reduced, and the effectiveness of secondary medication or more is ensured.
Owner:许铁
XIAP-Targeted Prostate Cancer Therapy
InactiveUS20070027169A1BiocidePeptide/protein ingredientsProstate cancer cellMitochondria mediated apoptosis
A treatment for prostate cancer using cyclin-dependent kinase inhibitors is provided. The effects of cyclin-dependent kinase inhibitors on the survival of prostate cancer cells was examined. Roscovitine, R-roscovitine, and CGP74514A were shown to induce the apoptosis of LNCaP and LNCaP-Rf cells, both of which express wild-type p53. The cyclin-dependent kinase inhibitors of the present invention induce the mitochondria-mediated apoptosis of prostate cancer cells by a dual mechanism: p53 accumulation and XIAP depletion.
Owner:UNIV OF SOUTH FLORIDA
Small Molecule Antagonists of Xiap Family Proteins
The present invention relates to naturally occurring and chemically synthesized small molecule antagonists of XIAP family proteins. In particular, the present invention provides embelin and other XIAP inhibitors and methods of using these compounds as antagonists of the anti-apoptotic effects of XIAP family member proteins. The present invention also provides methods for treating diseases and pathologies (e.g., neoplastic diseases).
Owner:RGT UNIV OF MICHIGAN
Recombinant TAT-XIAP fusion protein
The invention belongs to the technical field of gene engineering, and particularly relates to a fusion protein formed by fusing a protein transduction domain (PTD) coded by TAT (trans-activator of transcription) genes of HIV (human immunodeficiency viruses) and an X-linked inhibitor of apoptosis protein (XIAP) nucleotide sequence. The amino acid sequence of the fusion protein is expressed as SEQ ID No: 1. Compared with the prior art, the original XIAP genes with nucleotide sequence expressed as SEQ ID No: 3 are optimized by using escherichia coli preferred codons so that the original XIAP genes are efficiently expressed in escherichia coli, the defect that the XIAP cannot stride the blood brain barrier or enter the brain to play a role in apoptosis resistance is made up by using the transduction capability of the PTD coded by the TAT genes of the HIV so that the final expression product of the genes can enter the brain tissue cells to play a role in cell apoptosis resistance, and the fusion protein is used for therapy and research of central nervous system diseases.
Owner:GUILIN MEDICAL UNIVERSITY
Biomarker of granulosa cells used for polycystic ovary syndrome (PCOS) diagnosis, and screening method and diagnostic kit thereof
PendingCN110747269AGood technical versatilityQuick fixMicrobiological testing/measurementGranular leucocyteGranulosa cell
The invention relates to a biomarker of granulosa cells used for polycystic ovary syndrome (PCOS) diagnosis as well as a screening method and a diagnostic kit thereof. The novel diagnostic biomarker is discovered by screening PCOS-related biomarkers in the whole genome by adopting combined analysis of RNA-seq, miRNA-seq and MBD-seq. The biomarker comprises miR-429, miR-141-3p and miR-126-3p, and / or XIAP gene, BRD3 gene, MAPK14 gene and SLC7A5 gene. Compared with the prior art, the biomarker of granulosa cells used for PCOS diagnosis has the advantages of being high in detection sensitivity, high in accuracy and so on.
Owner:SHANGHAI JIAO TONG UNIV
TRAIL double target mutant protein MuR5S4TR, and preparation method and application thereof
ActiveCN106459172AImprove structural stabilityImprove biological activityPeptide/protein ingredientsTumor necrosis factorMutated proteinTRAIL Protein
Owner:CHENGDU HUACHUANG BIOTECH CO LTD
Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid (sina)
InactiveUS20070093437A1Improve bioavailabilityMinimize the possibilityCompounds screening/testingSpecial deliveryRegulator geneDouble strand
This invention relates to compounds, compositions, and methods useful for modulating XIAP gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of XIAP gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of XIAP genes.
Owner:SIRNA THERAPEUTICS INC
Anti-tumor polypeptide Sur-X targeting to survivin-XIAP complex and application
ActiveCN110713546AEasy to synthesizeConvenient for clinical operationPolypeptide with localisation/targeting motifPeptide/protein ingredientsGastric tumorXIAP
The invention relates to the field of targeted treatment medicines for tumors and in particular relates to an anti-tumor polypeptide Sur-X targeting to a survivin-XIAP complex and application of the anti-tumor polypeptide Sur-X in treatment on multiple tumors including colorectal cancer and gastric cancer. The anti-tumor polypeptide Sur-X provided by the invention is capable of rapidly and efficiently inducing death of colorectal and gastric cancer cells by inhibiting formation of the survivin-XIAP complex, does not affect normal cells of human beings, and thus takes a treatment effect of specifically targeting to tumor cells. In addition, the polypeptide is easy to synthesize in vitro, and is convenient in clinical application. Therefore, the polypeptide Sur-X has potential commercial andindustrial value and can be widely used in the technical field of targeted treatment on tumors.
Owner:THE FIRST HOSPITAL OF CHINA MEDICIAL UNIV
Organic Compounds
Owner:NOVARTIS AG
Anti-tumor diazo dicyclic apoptosis protein inhibitor
ActiveCN110028508AEnhanced inhibitory effectReduce inhibitionOrganic active ingredientsOrganic chemistryApoptosisMda mb 231
Owner:NANJING HUAWE MEDICINE TECH DEV
Method of treating hearing loss using xiap
InactiveUS20110171202A1Preventing hearing lossPrevent the hearing lossSenses disorderVirusesInhibitor of apoptosisImpaired Balance
Disclosed is a method of treating or preventing hearing loss in a subject. The method comprises administering to the subject in need thereof, an adeno-associated viral expression vector encoding X-linked inhibitor of apoptosis protein (XIAP). The XIAP is positioned in the vector for expression in an inner ear organ, or associated neural structures, of the subject so as to treat or prevent the hearing loss. Also disclosed is a method of treating or preventing impaired balance.
Owner:AUDIGEN
Application of isorhapontigenin (ISO) to preparation of drugs with antitumor activity
InactiveCN103191083AInhibit apoptosisPromote apoptosisOrganic active ingredientsAntineoplastic agentsInhibitor of apoptosisGene expression level
The invention discloses application of isorhapontigenin (ISO) to preparation of drugs with antitumor activity. The activity of the X-linked inhibitor of apoptosis protein (XIAP) is inhibited by lowering gene expression of the XIAP. Western-blotting, reverse transcription-polymerase chain reaction (RT-PCR), an adenosine triphosphate (ATP) bioluminescence detection method, chromatin immunoprecipitation (CHIP) and other methods are utilized to prove that the XIAP gene expression level can be obviously inhibited, then tumor cell apoptosis is induced and tumor cell proliferation is inhibited by pretreating various tumor cells with ISO, ISO can not obviously induce tumor cell proliferation and apoptosis, the endogenous XIAP gene is the effective target treated with ISO and ISO is used for specifically inhibiting gene expression of the XIAP. Experiments prove that ISO can effectively improve the sensitivity of chemotherapy drugs and promote tumor cell apoptosis and has extensive application prospects in foundation medicine, clinical treatment, new drug research and development and the like.
Owner:ZHEJIANG UNIV
Organic compounds
Owner:NOVARTIS AG
Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity
InactiveUS20070128677A1Inhibitory activityReduce processingCompound screeningNervous disorderProtein regulationInhibitor of apoptosis
Owner:SANFORD BURNHAM MEDICAL RES INST
Novel agents targeting inhibitor of apoptosis proteins
Disclosed herein, inter alia, are methods of use and composition of novel inhibitors that target the Smac binding site of a variety of inhibitor of apoptosis proteins that contain a Bir domain, including XIAP, cIAP1, cIAP2, or other IAP proteins.
Owner:RGT UNIV OF CALIFORNIA
Isoquinoline compounds capable of inhibiting inhibitor-of-apoptosis proteins and preparation method and application of isoquinoline compounds
InactiveCN103965165AReduced activityPromote degradationOrganic chemistryAntineoplastic agentsDrug biological activityBiomedicine
The invention belongs to the field of biomedical technology and particularly relates to isoquinoline compounds capable of inhibiting inhibitor-of-apoptosis proteins and a preparation method and an application of the isoquinoline compounds. According to the invention, a series of isoquinoline compounds capable of being interacted with a BIR2 structural domain of an IAP family are designed and synthesized, so that the activities of various IAPs are decreased; on one hand, an inhibition effect of XIAP on Caspase-3 is antagonized, and on the other hand, the ubiquitination of cIAP and degradation of proteasome are promoted and thus the isoquinoline compounds have biological activity against the growth of ovarian cancer. The isoquinoline compounds disclosed by the invention play roles in resisting ovarian cancer and reversing the drug resistance to ovarian cancer by inhibiting IAPs, and the roles can be confirmed by CCK-8 and a large number of experiments, such as in vivo nude mice subcutaneously transplanted tumors experiment. The compounds disclosed by the invention have the advantages of small molecular mass, high oral bioavailability, flexibility in clinical medication and relatively high anti-tumor activity; combined with the BIR2 structural domains of various IAPs, the compounds have broader action objects and action routes, and have more advantages in clinical application.
Owner:FUDAN UNIV
Experimental method for rabbit KOA model chondrocytes by adopting medicine scraping method
PendingCN112666351AFree from destructionReduce degenerationPreparing sample for investigationMaterial analysis by optical meansArticulatio genusSenescence
The invention provides an experimental method for rabbit KOA model chondrocytes by adopting a medicine scraping method, which is characterized by comprising the following steps: 1, establishing a rabbit KOA model; 2, regularly smearing the knee joint of the rabbit with the berchemia lineate massage cream by adopting a medicine scraping method; 3, preparing an animal specimen; 4, performing morphological observation on cartilage tissue in the specimen; and 5, carrying out immunohistochemical detection on caspase-3, caspase-9 and XIAP proteins in the cartilage tissue. The research of the invention proves that the medicine scraping method can reduce the expression quantity of caspase-3 and caspase-9 in the rabbit articular cartilage of the K0A model and up-regulate the content of XIAP in cytobiology, so that the articular cartilage is protected from being damaged, and the joint senescence is delayed.
Owner:湖南省中医药研究院
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap